141 related articles for article (PubMed ID: 21847521)
1. Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases.
Harada K; Miyake H; Kurahashi T; Fujisawa M
Clin Exp Nephrol; 2011 Dec; 15(6):966-9. PubMed ID: 21847521
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
[TBL] [Abstract][Full Text] [Related]
4. [Successful treatment for renal cell carcinoma with lung metastases by interleukin-2 and interferon-alfa: a case report].
Sakata Y; Ogura Y; Wakita T; Hayashi N; Sugimura Y
Hinyokika Kiyo; 2003 Jul; 49(7):389-91. PubMed ID: 12968479
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
7. Metastatic type-2 papillary renal cell carcinoma responded to interleukin-2 therapy: case report.
Kosaka T; Mikami S; Miyajima A; Oya M
Clin Exp Nephrol; 2008 Apr; 12(2):155-158. PubMed ID: 18209950
[TBL] [Abstract][Full Text] [Related]
8. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
[TBL] [Abstract][Full Text] [Related]
12. Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon alpha in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment.
Huland E; Heinzer H; Huland H
J Cancer Res Clin Oncol; 1994; 120(4):221-8. PubMed ID: 8288676
[TBL] [Abstract][Full Text] [Related]
13. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
[TBL] [Abstract][Full Text] [Related]
14. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
[TBL] [Abstract][Full Text] [Related]
15. [Inhaled immunotherapy for pulmonary metastases of renal cell cancer].
Lümmen G; Schenck M; Börgermann C; Eisenhardt A; Vom Dorp F; Sperling H; Rübben H
Urologe A; 2004 Apr; 43(4):457-61. PubMed ID: 15085267
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
17. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
18. [A case of multiple lung metastases and cervical lymph node metastasis of renal cell carcinoma failing to respond to interferon-alpha (IFN-alpha) but markedly responding to interleukin-2 (IL-2)].
Nishikimi T; Ishida R; Yamada H; Yokoi K; Kobayashi H; Obata K
Nihon Hinyokika Gakkai Zasshi; 2004 Jan; 95(1):54-8. PubMed ID: 14978942
[TBL] [Abstract][Full Text] [Related]
19. [Synergetic responses after administration of interleukin-2 and Interferon-alpha combined with gamma knife radiosurgery in a patient with multiple lung and brain metastases: a case report].
Takada T; Yamada Y; Uno M; Komeda H; Fujimoto Y
Hinyokika Kiyo; 2005 Jun; 51(6):381-4. PubMed ID: 16050476
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
